| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-11-19 |
| タイトル |
|
|
タイトル |
Factors associated with the effect of anamorelin on cachexia in patients with non-small cell lung cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
anamorelin |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
cachexia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
NSCLC |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Ishioka, Yoshiko
Tanaka, Hisashi
Makiguchi, Tomonori
Sakamoto, Hiroaki
Shiratori, Toshihiro
Taima, Kageaki
Tasaka, Sadatomo
|
| 著者所属 |
|
|
言語 |
en |
|
値 |
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
PURPOSE: Anamorelin, a ghrelin receptor agonist, is approved in Japan for the treatment of cachexia in patients with lung and gastrointestinal cancer. However, there is limited research on the usefulness of anamorelin in clinical settings.
METHODS: A total of 40 patients with non-small cell lung cancer and cachexia who were prescribed anamorelin between July 2021 and November 2022, were retrospectively assessed. A logistic regression analysis was used to analyze the association between background characteristics and early discontinuation of treatment with anamorelin （within 4 weeks）.
RESULTS: The median age was 67 years （range, 36-88）, and 65% of the patients were male. The early discontinuation group included 11 patients （27.5%）. An Eastern Cooperative Oncology Group Performance Status （ECOG-PS） score ≥2 （odds ratio, 7.85; 95% confidence interval, 1.43-43.21; P=0.018） was associated with early discontinuation. A total of 18/40 patients were able to continue anamorelin treatment for 12 weeks, and the mean change in body weight was +2.31 kg, which was a significant change from the weight recorded at baseline（ P=0.027）.
CONCLUSION: This study indicates that anamorelin is unlikely to be useful for patients with a poor general condition（ ECOG-PS score ≥2）. |
|
言語 |
en |
| 書誌情報 |
ja : 弘前医学
en : Hirosaki Medical Journal
巻 75,
号 1,
p. 22-30,
発行日 2024-10-30
|
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2434-4656 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00211444 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 出版者 |
|
|
出版者 |
弘前大学大学院医学研究科 |
|
言語 |
ja |
Hirosaki Med J 75-1_22.pdf (275 KB)
